Abstract

ABSTRACTNeuroblastoma (NB), although rare, accounts for 15% of all paediatric cancer mortality. Unusual among cancers, NBs lack a consistent set of gene mutations and, excluding large-scale chromosomal rearrangements, the genome seems to be largely intact. Indeed, many interesting features of NB suggest that it has little in common with adult solid tumours but instead has characteristics of a developmental disorder. NB arises overwhelmingly in infants under 2 years of age during a specific window of development and, histologically, NB bears striking similarity to undifferentiated neuroblasts of the sympathetic nervous system, its likely cells of origin. Hence, NB could be considered a disease of development arising when neuroblasts of the sympathetic nervous system fail to undergo proper differentiation, but instead are maintained precociously as progenitors with the potential for acquiring further mutations eventually resulting in tumour formation. To explore this possibility, we require a robust and flexible developmental model to investigate the differentiation of NB's presumptive cell of origin. Here, we use Xenopus frog embryos to characterise the differentiation of anteroventral noradrenergic (AVNA) cells, cells derived from the neural crest. We find that these cells share many characteristics with their mammalian developmental counterparts, and also with NB cells. We find that the transcriptional regulator Ascl1 is expressed transiently in normal AVNA cell differentiation but its expression is aberrantly maintained in NB cells, where it is largely phosphorylated on multiple sites. We show that Ascl1's ability to induce differentiation of AVNA cells is inhibited by its multi-site phosphorylation at serine-proline motifs, whereas overexpression of cyclin-dependent kinases (CDKs) and MYCN inhibit wild-type Ascl1-driven AVNA differentiation, but not differentiation driven by a phospho-mutant form of Ascl1. This suggests that the maintenance of ASCL1 in its multiply phosphorylated state might prevent terminal differentiation in NB, which could offer new approaches for differentiation therapy in NB.

Highlights

  • Neuroblastoma (NB) is a tumour of the autonomic nervous system and is the most common cancer diagnosed in the first year of life

  • They show that anteroventral noradrenergic (AVNA) cells derive from the neural crest and express a series of noradrenergic genetic markers that are shared with NB cells

  • Building on previous studies characterising posttranslational regulation of Ascl1, the authors demonstrate that, Ascl1 is present in NB, it is phosphorylated on multiple serine-proline sites and this inhibits its ability to drive AVNA cell differentiation

Read more

Summary

Introduction

Neuroblastoma (NB) is a tumour of the autonomic nervous system and is the most common cancer diagnosed in the first year of life. A stark dichotomy is seen among NB cases, with some forms undergoing spontaneous regression and showing a strong response to treatment whereas others progress to fatal metastasis and fail modern therapy (Maris, 2010). Genetic studies into NB revealed some large-scale chromosomal rearrangements and amplifications in some tumours; most notably MYCN amplification was found to be consistently associated with poor prognosis in NB (Schwab et al, 1983). Large-scale rearrangements and chromosomal losses are sometimes observed, NB seems to lack a consistent set of mutations as seen in many other cancers. More recent large-scale sequencing studies have revealed that NB tumours have an average of only 12 amino-acid-changing mutations per tumour, with the highest recurring mutated gene, ALK, being mutated in only 6-10% of tumours, suggesting that the genome of NB is largely intact (Molenaar et al, 2012; Pugh et al, 2013)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.